Skeletal Muscle Weakness: A Novel Treatable Trait in Asthma?

Hannu Kankaanranta; Pinja Ilmarinen

doi:10.1016/j.jaip.2023.02.015

Skeletal Muscle Weakness: A Novel Treatable Trait in Asthma?

Hannu Kankaanranta^*
, Pinja Ilmarinen

^*Corresponding author for this work

Seinäjoen keskussairaala VA

Research output: Contribution to journal › Editorial › Scientific

3 Citations (Scopus)

Original language	English
Pages (from-to)	1448-1449
Number of pages	2
Journal	Journal of Allergy and Clinical Immunology: In Practice
Volume	11
Issue number	5
DOIs	https://doi.org/10.1016/j.jaip.2023.02.015
Publication status	Published - May 2023
Publication type	B1 Journal article

Funding

H. Kankaanranta is an asthma and allergy research professor funded by the Hermann Krefting Foundation and his work is supported by Swedish Heart and Lung Foundation, Swedish Asthma & Allergy Foundation , ALF agreement (ALFGBG-966075; grant from the Swedish state under the agreement between the Swedish Government and the county councils), Swedish Research Council (2022-01022), Tampere Tuberculosis Foundation (Tampere, Finland), the Finnish Anti-Tuberculosis Association Foundation, and the Competitive State Research Financing of the Expert Responsibility Area of Tampere University Hospital (Tampere, Finland). H. Kankaanranta is an asthma and allergy research professor funded by the Hermann Krefting Foundation and his work is supported by Swedish Heart and Lung Foundation, Swedish Asthma & Allergy Foundation, ALF agreement (ALFGBG-966075; grant from the Swedish state under the agreement between the Swedish Government and the county councils), Swedish Research Council (2022-01022), Tampere Tuberculosis Foundation (Tampere, Finland), the Finnish Anti-Tuberculosis Association Foundation, and the Competitive State Research Financing of the Expert Responsibility Area of Tampere University Hospital (Tampere, Finland).Conflicts of interest: H. Kankaanranta reports personal fees for lectures and consulting from AstraZeneca, Boehringer-Ingelheim, Chiesi Pharma, GSK, MSD, Novartis, Orion Pharma, and Sanofi Genzyme, outside the submitted work. P. Ilmarinen is employed by GSK Finland as a scientific advisor.

ASJC Scopus subject areas

Immunology and Allergy

Access to Document

10.1016/j.jaip.2023.02.015

Cite this

@article{eabf11c537ba46ff9b25ad5dc95b1fbe,

title = "Skeletal Muscle Weakness: A Novel Treatable Trait in Asthma?",

author = "Hannu Kankaanranta and Pinja Ilmarinen",

note = "Funding Information: H. Kankaanranta is an asthma and allergy research professor funded by the Hermann Krefting Foundation and his work is supported by Swedish Heart and Lung Foundation, Swedish Asthma \& Allergy Foundation , ALF agreement (ALFGBG-966075; grant from the Swedish state under the agreement between the Swedish Government and the county councils), Swedish Research Council (2022-01022), Tampere Tuberculosis Foundation (Tampere, Finland), the Finnish Anti-Tuberculosis Association Foundation, and the Competitive State Research Financing of the Expert Responsibility Area of Tampere University Hospital (Tampere, Finland). Funding Information: H. Kankaanranta is an asthma and allergy research professor funded by the Hermann Krefting Foundation and his work is supported by Swedish Heart and Lung Foundation, Swedish Asthma \& Allergy Foundation, ALF agreement (ALFGBG-966075; grant from the Swedish state under the agreement between the Swedish Government and the county councils), Swedish Research Council (2022-01022), Tampere Tuberculosis Foundation (Tampere, Finland), the Finnish Anti-Tuberculosis Association Foundation, and the Competitive State Research Financing of the Expert Responsibility Area of Tampere University Hospital (Tampere, Finland).Conflicts of interest: H. Kankaanranta reports personal fees for lectures and consulting from AstraZeneca, Boehringer-Ingelheim, Chiesi Pharma, GSK, MSD, Novartis, Orion Pharma, and Sanofi Genzyme, outside the submitted work. P. Ilmarinen is employed by GSK Finland as a scientific advisor.",

year = "2023",

month = may,

doi = "10.1016/j.jaip.2023.02.015",

language = "English",

volume = "11",

pages = "1448--1449",

journal = "Journal of Allergy and Clinical Immunology: In Practice",

issn = "2213-2198",

publisher = "American Academy of Allergy, Asthma and Immunology",

number = "5",

}

TY - JOUR

T1 - Skeletal Muscle Weakness

T2 - A Novel Treatable Trait in Asthma?

AU - Kankaanranta, Hannu

AU - Ilmarinen, Pinja

N1 - Funding Information: H. Kankaanranta is an asthma and allergy research professor funded by the Hermann Krefting Foundation and his work is supported by Swedish Heart and Lung Foundation, Swedish Asthma & Allergy Foundation , ALF agreement (ALFGBG-966075; grant from the Swedish state under the agreement between the Swedish Government and the county councils), Swedish Research Council (2022-01022), Tampere Tuberculosis Foundation (Tampere, Finland), the Finnish Anti-Tuberculosis Association Foundation, and the Competitive State Research Financing of the Expert Responsibility Area of Tampere University Hospital (Tampere, Finland). Funding Information: H. Kankaanranta is an asthma and allergy research professor funded by the Hermann Krefting Foundation and his work is supported by Swedish Heart and Lung Foundation, Swedish Asthma & Allergy Foundation, ALF agreement (ALFGBG-966075; grant from the Swedish state under the agreement between the Swedish Government and the county councils), Swedish Research Council (2022-01022), Tampere Tuberculosis Foundation (Tampere, Finland), the Finnish Anti-Tuberculosis Association Foundation, and the Competitive State Research Financing of the Expert Responsibility Area of Tampere University Hospital (Tampere, Finland).Conflicts of interest: H. Kankaanranta reports personal fees for lectures and consulting from AstraZeneca, Boehringer-Ingelheim, Chiesi Pharma, GSK, MSD, Novartis, Orion Pharma, and Sanofi Genzyme, outside the submitted work. P. Ilmarinen is employed by GSK Finland as a scientific advisor.

PY - 2023/5

Y1 - 2023/5

U2 - 10.1016/j.jaip.2023.02.015

DO - 10.1016/j.jaip.2023.02.015

M3 - Editorial

AN - SCOPUS:85153400296

SN - 2213-2198

VL - 11

SP - 1448

EP - 1449

JO - Journal of Allergy and Clinical Immunology: In Practice

JF - Journal of Allergy and Clinical Immunology: In Practice

IS - 5

ER -